Jonathan Strosberg

University of South Florida — United States

Medicine · Health Sciences

70h-index20.9kcitations429works4.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroendocrine Tumor Research Advances(346), Lung Cancer Research Studies(276), Neuroblastoma Research and Treatments(256), Pancreatic and Hepatic Oncology Research(60), Gestational Trophoblastic Disease Studies(16)

Publications427 total

Emerging Diagnostics and Therapies in Neuroendocrine Neoplasms: A Critical Review
Cancers·2025· 2 citedOpen Access
Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy
Endocrine Pathology·2025· 1 cited
Association Between Long-Term Proton Pump Inhibitor Use and Low-Risk Gastric Neuroendocrine Tumors
Annals of Surgical Oncology·2025
The relationship between radiological features of DIPNECH, and clinical symptoms and physiology
2025
Clinical characteristics of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia
ERJ Open Research·2025· 1 citedOpen Access
Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202)
Journal of Clinical Oncology·2025· 1 citedOpen Access
1034MO Long-term follow-up of peptide receptor radionuclide therapy (PRRT)-naïve patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with targeted alpha therapy 212Pb-DOTAMTATE in the phase II ALPHAMEDIX 02 trial
Annals of Oncology·2025
1032O Efficacy and safety of targeted alpha therapy 212Pb-DOTAMTATE in patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) previously treated with peptide receptor radionuclide therapy (PRRT): Results of a phase II study
Annals of Oncology·2025
1712P Efficacy and safety of cabozantinib (CABO) for advanced lung and thymic neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of phase III CABINET Trial (Alliance A021602)
Annals of Oncology·2025
Peptide receptor radionuclide therapy in G3 gastroenteropancreatic neuroendocrine tumors: a missed opportunity for European patients?
The Lancet Regional Health - Europe·2025· 3 citedOpen Access
Consensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms
Annals of Surgical Oncology·2025· 1 cited
Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms
Cancer·2025· 1 cited
Somatostatin Receptor Expression of Gastroenteropancreatic Neuroendocrine Tumors: A Comprehensive Analysis in the Era of Somatostatin Receptor PET Imaging
Cancers·2025· 2 citedOpen Access
Health-related quality of life (HRQOL) in the phase 3 trial of cabozantinib vs placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET, Alliance A021602).
Journal of Clinical Oncology·2025· 1 cited
Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
JCO Oncology Practice·2025· 6 cited
Dipnech: Clinical Characteristics of an International Case Series
American Journal of Respiratory and Critical Care Medicine·2025
Relationship Between Best Tumor Shrinkage and Progression‐Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [ <scp> <sup>177</sup> Lu </scp> ]Lu‐ <scp>DOTA</scp> ‐ <scp>TATE</scp> : Ad Hoc Analysis of the Phase <scp>III NETTER</scp> ‐1 Trial
Cancer Medicine·2025· 4 citedOpen Access
Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis
Seminars in Cancer Biology·2025· 10 citedOpen Access
NETest® 2.0 - a decade of innovation in neuroendocrine tumor/neoplasm diagnostics
Endocrine Abstracts·2025
A novel hormone based anti-SSTR bispecific T-cell engager for the treatment of neuroendocrine tumorrs
Endocrine Abstracts·2025
page 1 of 22Next →

Frequent Co-authors

Matthew H. Kulke(16), James C. Yao(14), Pamela L. Kunz(12), Al B. Benson(11), Emily K. Bergsland(10), Larry K. Kvols(9), Diane Reidy‐Lagunes(9), Manisha H. Shah(9), Edward M. Wolin(7), Jordan Berlin(6), Domenico Coppola(6), Jennifer A. Chan(6), Þorvarður R. Hálfdánarson(6), David C. Metz(6), Thomas M. O’Dorisio(5), Kjell Öberg(5), Simron Singh(5), David S. Klimstra(5), Martin J. Heslin(5), Paul F. Engstrom(5)